摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-氟-3-硝基苯硼酸 | 352530-22-4

中文名称
4-氟-3-硝基苯硼酸
中文别名
——
英文名称
(4-fluoro-3-nitrophenyl)boronic acid
英文别名
3-nitro-4-fluorophenylboronic acid;4-Fluoro-3-nitrophenylboronic acid
4-氟-3-硝基苯硼酸化学式
CAS
352530-22-4
化学式
C6H5BFNO4
mdl
MFCD08277236
分子量
184.919
InChiKey
JDPKQZFQCPEJNH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    367.0±52.0 °C(Predicted)
  • 密度:
    1.49±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.73
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    86.3
  • 氢给体数:
    2
  • 氢受体数:
    5

安全信息

  • 海关编码:
    2931900090
  • 危险性防范说明:
    P280,P305+P351+P338
  • 危险性描述:
    H302

SDS

SDS:14b3fda99ac8d1af054e1a0dc5496849
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 4-Fluoro-3-nitrophenylboronic acid
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 4-Fluoro-3-nitrophenylboronic acid
CAS number: 352530-22-4

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H5BFNO4
Molecular weight: 184.9

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    [EN] HYDROPHOBICALLY TAGGED SMALL MOLECULES AS INDUCERS OF PROTEIN DEGRADATION
    [FR] PETITES MOLÉCULES MARQUÉES DE FAÇON HYDROPHOBE EN TANT QU'INDUCTEURS DE LA DÉGRADATION DE PROTÉINE
    摘要:
    提供了化学式(I)的双功能小分子,或其药用盐,其中M代表一个小有机分子,可以共价或非共价结合激酶,如Her3蛋白激酶;L1代表一个连接物;RH代表一个疏水基团。化合物化学式(I)的一个例子是化合物化学式(II)。还提供了包含化学式(I)或(II)的药物组合物,以及使用这些化合物治疗增殖性疾病的方法。
    公开号:
    WO2014063061A1
  • 作为产物:
    描述:
    4-氟苯硼酸硝酸 作用下, 以 乙醇 为溶剂, 以31.5%的产率得到4-氟-3-硝基苯硼酸
    参考文献:
    名称:
    一种合成3-氨基-4-氟苯硼酸的方法
    摘要:
    本发明属于有机化学物合成领域。一种合成3-氨基-4-氟苯硼酸的方法,包括以下三个步骤:第一步将对氟溴苯制成格氏试剂,然后与硼酸三甲酯反应得到中间体对氟苯硼酸A;第二步中间体A与发烟硝酸反应生成中间体3-硝基-4-氟苯硼酸B;第三步中间体B在钯碳的催化下加氢生成产品3-氨基-4-氟苯硼酸C。本发明合成方法原料易得、操作简单,成本较低,提供一种制备3-氨基-4-氟苯硼酸的适宜路径。
    公开号:
    CN103626791B
点击查看最新优质反应信息

文献信息

  • [EN] HETEROCYCLIC SUBSTITUTED UREAS, FOR USE AGAINST CANCER<br/>[FR] URÉES SUBSTITUÉES HÉTÉROCYCLIQUES, DESTINÉES À ÊTRE UTILISÉES CONTRE LE CANCER
    申请人:ARTIOS PHARMA LTD
    公开号:WO2020030925A1
    公开(公告)日:2020-02-13
    The application relates to heterocyclic urea derivatives and their use in the treatment and prophylaxis of cancer, and to compositions containing said derivatives and processes for their preparation.
    该应用涉及杂环生物及其在癌症治疗和预防中的应用,以及含有这些衍生物的组合物和它们的制备方法。
  • [EN] IDO INHIBITORS<br/>[FR] INHIBITEURS DE L'IDO
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2014150646A1
    公开(公告)日:2014-09-25
    There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention. Formula (I).
    已披露的化合物可调节或抑制色胺酸2,3-二氧化酶(IDO)的酶活性,含有该化合物的药物组合物以及利用本发明的化合物治疗增殖性疾病,如癌症、病毒感染和/或自身免疫疾病的方法。公式(I)。
  • [EN] HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROARYLE SERVANT D'INHIBITEURS D'IRAK, ET LEURS UTILISATIONS
    申请人:MERCK PATENT GMBH
    公开号:WO2017049069A1
    公开(公告)日:2017-03-23
    The present invention relates to compounds of Formula (I) and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    本发明涉及式(I)的化合物及其药用可接受的组合物,作为IRAK抑制剂
  • KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES
    申请人:Flynn L. Daniel
    公开号:US20080090856A1
    公开(公告)日:2008-04-17
    The present invention is concerned with novel compounds useful in the treatment of hyperproliferative diseases and mammalian cancers, especially human cancers. The invention also pertains to methods of modulating kinase activities, pharmaceutical compositions, and methods of treating individuals, incorporating or using the compounds. The preferred compounds are active small molecules set forth in formulae Ia-Iww.
    本发明涉及一种在治疗高增殖性疾病和哺乳动物癌症,尤其是人类癌症方面有用的新化合物。该发明还涉及调节激酶活性的方法、药物组合物以及治疗个体的方法,包括或使用这些化合物。优选的化合物是在公式Ia-Iww中列出的活性小分子。
  • [EN] NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS MACROCYCLIQUES INHIBITEURS DE PTEFB
    申请人:BAYER AG
    公开号:WO2018177889A1
    公开(公告)日:2018-10-04
    The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    本发明涉及一种新型改性大环化合物,其通式(I)如本文所述和定义,具有改善的耐受性,以及其制备方法,它们用于治疗和/或预防疾病,特别是高增殖性疾病和/或病毒引起的传染病和/或心血管疾病。该发明还涉及在制备通式(I)所述化合物中有用的中间化合物。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫